IMPORTANT INFORMATION FOR PRIVATE INVESTORS

Our investments place your capital at risk. We do not provide investment, tax or legal advice and we recommend you seek professional advice if you are considering investing with us. You may lose part or all of the amount you invest with us. We invest in unquoted shares in small companies. The value of these shares can be volatile, and the shares are often difficult to sell. The tax reliefs associated with our investments depend on the individual circumstances of each investor and may be subject to change. Past performance is not a reliable indicator of future results. Our forecasts and performance targets cannot accurately predict how investments will perform.

ACCEPT DECLINE
Change Visitor Type Sign up to our newsletter

NEWS & VIEWS

Oxford Capital and our portfolio companies

Working towards an exit….what we learned from Latent Logic

By David Mott, Founder Partner, Oxford Capital | January 20, 2021
David Mott, Founder Partner, Oxford Capital As we start a new year, I’ve been reflecting on 2020 and all of the many challenges and opportunities that it brought.  It struck me that just over a year ago we handled our first deep tech exit of the year, the sale of Latent Logic to Waymo (part…
Read More

10 steps for getting setup with Salesforce – enhancing your CRM programme

By Simon Edwards, Manager, Investor Relations | January 20, 2021
1. Prepare yourselves – make time and plan From experience, one of the biggest hurdles setting up Salesforce is managing the project around existing workloads, not just for the team or individuals who will be leading the project, but also any other team using it or inputting data. Make a plan that focuses on balancing…
Read More

Push Doctor secures NHS partnership to provide digital healthcare for over 300,000 people

By Oxford Capital | January 19, 2021
Our portfolio company, Push Doctor has been chosen by Hounslow GP Practices (an area significantly impacted by Covid) to provide direct access to convenient digital NHS GP appointments for patients.      
Read More

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform

By Oxford Capital | January 19, 2021
Good news for our portfolio company, Oxford BioTherapeutics – OBT and WuXi Biologics have selected a second bispecific programme that will combine an anti-PD-L1 antibody with OBT’s immuno-oncology candidate, OX003.
Read More

Outplay Entertainment launches new game – Gordon Ramsay’s Chef Blast

By Oxford Capital | January 18, 2021
Portfolio company, Outplay Entertainment has teamed up with Gordon Ramsay to launch Chef Blast – a match two puzzle game.
Read More

Best startups to work for in London (2021) – Attest, Hometree and Moneybox feature

By Oxford Capital | January 13, 2021
A number of portfolio companies (Attest, Hometree and Moneybox) feature in this list from Tempo UK of the best startups to work for in London in 2021.
Read More

Portfolio company, Curve secures $95M in Series C funding

By Oxford Capital | January 12, 2021
Curve has secured $95M in Series C funding to support its US launch and deepen its expansion into Europe.  We first invested in Curve as an early stage company in 2017, back when it was a small, pre-revenue business with an energetic founder who really inspired us with his mission.    
Read More

Outplay Entertainment adds 30 staff as it plans ‘banner’ year in 2021

By Oxford Capital | January 7, 2021
Our portfolio company, Outplay Entertainment increased staff by 30 last year as revenues increased and it prepared for a number of launches in 2021.
Read More

Oxford BioTherapeutics and Kite establish cell therapy research collaboration

By Oxford Capital | January 6, 2021
Positive news for our portfolio company, Oxford BioTherapeutics, it has announced a research collaboration with Kite, the global leader in cell therapy to evaluate five novel targets for a number of hematologic and solid tumor indications.
Read More

EIS update (Intelligent Partnership) – commentary from Oxford Capital

By Oxford Capital | January 5, 2021
We feature in the latest EIS update from Intelligent Partnership, it includes an overview of the Oxford Capital Growth EIS and our views on the challenges and opportunities the industry faces in 2021.
Read More

Awards

  • BEST EIS
    FUND MANAGER    2013,2012,2010 AND 2006

  • VENTURE CAPITAL
    HOUSE OF THE YEAR    WINNER 2013 AND 2005

  • INVESTOR OF
    THE YEAR    WINNER IN 2012 AND 2013

  • MOST IMPACTFUL
    INVESTMENT    WINNER 2017

  • BEST ANGEL
    SYNDICATE    WINNER 2018

  • BVCA Excellence in ESG
    GP CATEGORY    COMMENDED 2020

  • VC INVESTOR OF THE YEAR
    GIANT HEALTH AWARDS    WINNER 2020

  • EXIT OF THE YEAR
    ONE TO WATCH    2020